Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole

A combined emulsion/polymer cross-linking/solvent evaporation technique was used to prepare magnetic chitosan microspheres (MCM) containing the anticancer drug, oxantrazole. A central composite experimental design was used to simultaneously evaluate a variety of formulation factors on a number of re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical research 1992-03, Vol.9 (3), p.390-397
Hauptverfasser: ELDIN HASSAN, E, PARISH, R. C, GALLO, J. M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 397
container_issue 3
container_start_page 390
container_title Pharmaceutical research
container_volume 9
creator ELDIN HASSAN, E
PARISH, R. C
GALLO, J. M
description A combined emulsion/polymer cross-linking/solvent evaporation technique was used to prepare magnetic chitosan microspheres (MCM) containing the anticancer drug, oxantrazole. A central composite experimental design was used to simultaneously evaluate a variety of formulation factors on a number of response variables, such as the percentage of oxantrazole entrapped in the MCM. In association with the study design, statistical optimization procedures indicated the factors that significantly influence MCM preparation and what levels of the factors are needed to produce optimum MCM. Entrapment of anticancer agents into biodegradable microspheres is difficult because of low aqueous drug solubility and porosity of the particles. The latter effect was circumvented by a chitosan cross-linking step that resulted in approximately 3% (w/w) oxantrazole entrapment in the MCM via the optimization procedures. The combined formulation and statistical optimization strategy provide a basis to develop other microparticulate systems and led to a dosage form that can be used for future in vivo investigations.
doi_str_mv 10.1023/A:1015803321609
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73027589</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73027589</sourcerecordid><originalsourceid>FETCH-LOGICAL-c281t-46a20ece88319af74b7a655be885a145b09cadc834626fa951362c4d4c5126de3</originalsourceid><addsrcrecordid>eNo9kE1LAzEYhIMotVbPnoQcxJOr-dxsvJXiFxR6UfBW3s1m28husiYpaH-9CxZPAzMPAzMIXVJyRwnj9_MHSqisCOeMlkQfoSmViheaiI9jNCWKiaJSgp6is5Q-CSEV1WKCJrSkQis-Rc1qyK53e9vgNsR-10F2wePQ4h423mZnsNm6HBJ43DsTQxq2NtqETfAZnHd-g_PWYvAjCt7YiGFjfb7F4Xv0IuxDZ8_RSQtdshcHnaH3p8e3xUuxXD2_LubLwrCK5kKUwIg1tqo41dAqUSsopaxHQwIVsibaQGMqLkpWtqAl5SUzohFGUlY2ls_QzV_vEMPXzqa87l0ytuvA27BLa8UJU7LSI3h1AHd1b5v1EF0P8Wd9uGXMrw85JANdG8dlLv1jUkjNFeO_77Jy3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73027589</pqid></control><display><type>article</type><title>Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>ELDIN HASSAN, E ; PARISH, R. C ; GALLO, J. M</creator><creatorcontrib>ELDIN HASSAN, E ; PARISH, R. C ; GALLO, J. M</creatorcontrib><description>A combined emulsion/polymer cross-linking/solvent evaporation technique was used to prepare magnetic chitosan microspheres (MCM) containing the anticancer drug, oxantrazole. A central composite experimental design was used to simultaneously evaluate a variety of formulation factors on a number of response variables, such as the percentage of oxantrazole entrapped in the MCM. In association with the study design, statistical optimization procedures indicated the factors that significantly influence MCM preparation and what levels of the factors are needed to produce optimum MCM. Entrapment of anticancer agents into biodegradable microspheres is difficult because of low aqueous drug solubility and porosity of the particles. The latter effect was circumvented by a chitosan cross-linking step that resulted in approximately 3% (w/w) oxantrazole entrapment in the MCM via the optimization procedures. The combined formulation and statistical optimization strategy provide a basis to develop other microparticulate systems and led to a dosage form that can be used for future in vivo investigations.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1023/A:1015803321609</identifier><identifier>PMID: 1614973</identifier><identifier>CODEN: PHREEB</identifier><language>eng</language><publisher>New York, NY: Springer</publisher><subject>Anthraquinones - administration &amp; dosage ; Antineoplastic Agents - administration &amp; dosage ; Biological and medical sciences ; Chitin - analogs &amp; derivatives ; Chitin - chemistry ; Chitosan ; Drug Carriers ; General pharmacology ; Medical sciences ; Microspheres ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Pyrazoles - administration &amp; dosage</subject><ispartof>Pharmaceutical research, 1992-03, Vol.9 (3), p.390-397</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c281t-46a20ece88319af74b7a655be885a145b09cadc834626fa951362c4d4c5126de3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5459372$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1614973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ELDIN HASSAN, E</creatorcontrib><creatorcontrib>PARISH, R. C</creatorcontrib><creatorcontrib>GALLO, J. M</creatorcontrib><title>Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><description>A combined emulsion/polymer cross-linking/solvent evaporation technique was used to prepare magnetic chitosan microspheres (MCM) containing the anticancer drug, oxantrazole. A central composite experimental design was used to simultaneously evaluate a variety of formulation factors on a number of response variables, such as the percentage of oxantrazole entrapped in the MCM. In association with the study design, statistical optimization procedures indicated the factors that significantly influence MCM preparation and what levels of the factors are needed to produce optimum MCM. Entrapment of anticancer agents into biodegradable microspheres is difficult because of low aqueous drug solubility and porosity of the particles. The latter effect was circumvented by a chitosan cross-linking step that resulted in approximately 3% (w/w) oxantrazole entrapment in the MCM via the optimization procedures. The combined formulation and statistical optimization strategy provide a basis to develop other microparticulate systems and led to a dosage form that can be used for future in vivo investigations.</description><subject>Anthraquinones - administration &amp; dosage</subject><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Biological and medical sciences</subject><subject>Chitin - analogs &amp; derivatives</subject><subject>Chitin - chemistry</subject><subject>Chitosan</subject><subject>Drug Carriers</subject><subject>General pharmacology</subject><subject>Medical sciences</subject><subject>Microspheres</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrazoles - administration &amp; dosage</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1LAzEYhIMotVbPnoQcxJOr-dxsvJXiFxR6UfBW3s1m28husiYpaH-9CxZPAzMPAzMIXVJyRwnj9_MHSqisCOeMlkQfoSmViheaiI9jNCWKiaJSgp6is5Q-CSEV1WKCJrSkQis-Rc1qyK53e9vgNsR-10F2wePQ4h423mZnsNm6HBJ43DsTQxq2NtqETfAZnHd-g_PWYvAjCt7YiGFjfb7F4Xv0IuxDZ8_RSQtdshcHnaH3p8e3xUuxXD2_LubLwrCK5kKUwIg1tqo41dAqUSsopaxHQwIVsibaQGMqLkpWtqAl5SUzohFGUlY2ls_QzV_vEMPXzqa87l0ytuvA27BLa8UJU7LSI3h1AHd1b5v1EF0P8Wd9uGXMrw85JANdG8dlLv1jUkjNFeO_77Jy3g</recordid><startdate>19920301</startdate><enddate>19920301</enddate><creator>ELDIN HASSAN, E</creator><creator>PARISH, R. C</creator><creator>GALLO, J. M</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19920301</creationdate><title>Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole</title><author>ELDIN HASSAN, E ; PARISH, R. C ; GALLO, J. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c281t-46a20ece88319af74b7a655be885a145b09cadc834626fa951362c4d4c5126de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Anthraquinones - administration &amp; dosage</topic><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Biological and medical sciences</topic><topic>Chitin - analogs &amp; derivatives</topic><topic>Chitin - chemistry</topic><topic>Chitosan</topic><topic>Drug Carriers</topic><topic>General pharmacology</topic><topic>Medical sciences</topic><topic>Microspheres</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrazoles - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ELDIN HASSAN, E</creatorcontrib><creatorcontrib>PARISH, R. C</creatorcontrib><creatorcontrib>GALLO, J. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ELDIN HASSAN, E</au><au>PARISH, R. C</au><au>GALLO, J. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole</atitle><jtitle>Pharmaceutical research</jtitle><addtitle>Pharm Res</addtitle><date>1992-03-01</date><risdate>1992</risdate><volume>9</volume><issue>3</issue><spage>390</spage><epage>397</epage><pages>390-397</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><coden>PHREEB</coden><abstract>A combined emulsion/polymer cross-linking/solvent evaporation technique was used to prepare magnetic chitosan microspheres (MCM) containing the anticancer drug, oxantrazole. A central composite experimental design was used to simultaneously evaluate a variety of formulation factors on a number of response variables, such as the percentage of oxantrazole entrapped in the MCM. In association with the study design, statistical optimization procedures indicated the factors that significantly influence MCM preparation and what levels of the factors are needed to produce optimum MCM. Entrapment of anticancer agents into biodegradable microspheres is difficult because of low aqueous drug solubility and porosity of the particles. The latter effect was circumvented by a chitosan cross-linking step that resulted in approximately 3% (w/w) oxantrazole entrapment in the MCM via the optimization procedures. The combined formulation and statistical optimization strategy provide a basis to develop other microparticulate systems and led to a dosage form that can be used for future in vivo investigations.</abstract><cop>New York, NY</cop><pub>Springer</pub><pmid>1614973</pmid><doi>10.1023/A:1015803321609</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0724-8741
ispartof Pharmaceutical research, 1992-03, Vol.9 (3), p.390-397
issn 0724-8741
1573-904X
language eng
recordid cdi_proquest_miscellaneous_73027589
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Anthraquinones - administration & dosage
Antineoplastic Agents - administration & dosage
Biological and medical sciences
Chitin - analogs & derivatives
Chitin - chemistry
Chitosan
Drug Carriers
General pharmacology
Medical sciences
Microspheres
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Pyrazoles - administration & dosage
title Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T12%3A52%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimized%20formulation%20of%20magnetic%20chitosan%20microspheres%20containing%20the%20anticancer%20agent,%20oxantrazole&rft.jtitle=Pharmaceutical%20research&rft.au=ELDIN%20HASSAN,%20E&rft.date=1992-03-01&rft.volume=9&rft.issue=3&rft.spage=390&rft.epage=397&rft.pages=390-397&rft.issn=0724-8741&rft.eissn=1573-904X&rft.coden=PHREEB&rft_id=info:doi/10.1023/A:1015803321609&rft_dat=%3Cproquest_pubme%3E73027589%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73027589&rft_id=info:pmid/1614973&rfr_iscdi=true